Oral Antibiotics Market By Class (Beta Lactam and Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), By Spectrum of Activity (Broad-spectrum Antibiotic, Mid/Narrow-spectrum antibiotic), By Application (Community-acquired respiratory tract infections (CARTIs), Urinary tract infections (UTIs), Dental, Others), By Drug Origin (Natural, Semisynthetic, Synthetic), By Drug Type (Branded, Generic): Global Opportunity Analysis and Industry Forecast, 2023-2032
The Oral Antibiotics Market was valued at $22,468.27 million in 2022 and is estimated to reach $28,819.98 million by 2032, exhibiting a CAGR of 2.5% from 2023 to 2032.
Oral antibiotics are medications that are administered by the mouth and designed to treat bacterial infections. They are ingested as tablets, capsules, or liquids, and are absorbed into the bloodstream through the digestive system. Oral antibiotics work by either killing the bacteria (bactericidal) or inhibiting their growth and reproduction (bacteriostatic). They achieve this by targeting specific bacterial structures or processes essential for their survival, such as inhibiting cell wall synthesis, disrupting protein synthesis, or interfering with DNA replication.
The choice of oral antibiotic is influenced by factors such as the spectrum of activity (the range of bacteria the antibiotic is effective against), its pharmacokinetic properties (absorption, distribution, metabolism, and excretion), the safety profile of drugs, and the susceptibility of the bacteria to the antibiotic. Some common classes of oral antibiotics include penicillin, cephalosporins, macrolides, fluoroquinolones, tetracyclines, and sulfonamides.
The growth of the oral antibiotic market is mainly attributed to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. Bacterial infections, ranging from common respiratory tract infections to more severe infections such as urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs), continue to affect a substantial portion of the population across the globe. For instance, according to an article by Medscape in 2023, urinary tract infections (UTIs) are common in the U.S., with at least 20% of women affected by one UTI in their lifetime. In addition, the growth in population, urbanization, and change in lifestyle factors contribute to the increased prevalence of infectious diseases and thereby driving market growth.
Furthermore, the aging population and the prevalence of chronic diseases also drive the oral antibiotics market. The elderly population and individuals with chronic conditions have a higher risk of developing infections due to weakened immune systems. Thus, increase in prevalence of these conditions drives the demand for oral antibiotics to prevent and treat associated infections.
Moreover, advancements in antibiotic development play a crucial role in driving the oral antibiotics market. Continuous R&D efforts have led to the discovery of new oral antibiotics with improved efficacy, expanded spectrum of activity, and reduced side effects. These advancements meet the unmet medical needs and improve patient outcomes, driving market growth.
However, the oral antibiotic market faces certain restraints that may impede its growth and development. The emergence and spread of antibiotic resistance pose a significant challenge. Over time, bacteria can develop resistance to the antibiotics, making them less effective in treating infections. This necessitates the development of new antibiotics or alternative treatment options, which can be time-consuming and costly. In addition, stringent regulations and guidelines related to antibiotic use and its prescription contribute to the challenges in the development and market availability of antibiotics drugs. This may hinder market growth.
Furthermore, increase in awareness about the importance of timely and appropriate treatment for bacterial infections has led to higher demand for antibiotic medications. Healthcare professionals and public health campaigns emphasizing the appropriate use of antibiotics have contributed to this awareness, thereby boosting the market demand.
The oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides and others. Beta lactam & beta lactamase inhibitors are further segmented into penicillin, cephalosporin and others. On the basis of application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental and others. Community- respiratory tract infections (CARTIS) is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs). On the basis of drug origin, the market is categorized into natural, semisynthetic and synthetic. On the basis of spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and mid/narrow-spectrum antibiotic. On the basis of drug type, the market is divided into branded and generics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antibiotics market analysis from 2022 to 2032 to identify the prevailing oral antibiotics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the oral antibiotics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global oral antibiotics market trends, key players, market segments, application areas, and market growth strategies.
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data
Key Market Segments
By Application
Community-acquired respiratory tract infections (CARTIs)
Type
Upper Respiratory Tract Infections
Lower Respiratory Tract Infections
Urinary tract infections (UTIs)
Dental
Others
By Class
Beta Lactam and Beta Lactamase Inhibitors
Type
Penicillin
◦ Spectrum of Activity
Cephalosporin
Others
Quinolone
Macrolide
Others
By Spectrum of Activity
Broad-spectrum Antibiotic
Mid/Narrow-spectrum antibiotic
By Drug Origin
Natural
Semisynthetic
Synthetic
By Drug Type
Branded
Generic
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Alkem Laboratories Ltd.
Lupin
Bayer AG
Teva Pharmaceutical Industries Limited
Abbott Laboratories
Novartis AG
Cipla Ltd
SUN PHARMACEUTICAL INDUSTRIES LIMITED
F. Hoffmann-La Roche Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of infectious diseases
- 3.4.1.2. Increase in consumption of oral antibiotics
- 3.4.1.3. Rise in investments in R&D activities
- 3.4.2. Restraints
- 3.4.2.1. Development of antibiotic resistance
- 3.4.2.2. Time consuming approvals
- 3.4.3. Opportunities
- 3.4.3.1. Discovery of advanced therapies to treat antibiotic- resistance.
- CHAPTER 4: ORAL ANTIBIOTICS MARKET, BY CLASS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Beta Lactam and Beta Lactamase Inhibitors
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Beta Lactam and Beta Lactamase Inhibitors Oral Antibiotics Market by Type
- 4.2.4.1. Penicillin Oral Antibiotics Market by Spectrum of Activity
- 4.3. Quinolone
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Macrolide
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- CHAPTER 5: ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Broad-spectrum Antibiotic
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Mid/Narrow-spectrum antibiotic
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: ORAL ANTIBIOTICS MARKET, BY APPLICATION
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Community-acquired respiratory tract infections (CARTIs)
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.2.4. Community-acquired respiratory tract infections (CARTIs) Oral Antibiotics Market by Type
- 6.3. Urinary tract infections (UTIs)
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Dental
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- 6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
- CHAPTER 7: ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Natural
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Semisynthetic
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- 7.4. Synthetic
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
- CHAPTER 8: ORAL ANTIBIOTICS MARKET, BY DRUG TYPE
- 8.1. Overview
- 8.1.1. Market size and forecast
- 8.2. Branded
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by region
- 8.2.3. Market share analysis by country
- 8.3. Generic
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by region
- 8.3.3. Market share analysis by country
- CHAPTER 9: ORAL ANTIBIOTICS MARKET, BY REGION
- 9.1. Overview
- 9.1.1. Market size and forecast By Region
- 9.2. North America
- 9.2.1. Key market trends, growth factors and opportunities
- 9.2.2. Market size and forecast, by Class
- 9.2.3. Market size and forecast, by Spectrum of Activity
- 9.2.4. Market size and forecast, by Application
- 9.2.5. Market size and forecast, by Drug Origin
- 9.2.6. Market size and forecast, by Drug Type
- 9.2.7. Market size and forecast, by country
- 9.2.7.1. U.S.
- 9.2.7.1.1. Market size and forecast, by Class
- 9.2.7.1.2. Market size and forecast, by Spectrum of Activity
- 9.2.7.1.3. Market size and forecast, by Application
- 9.2.7.1.4. Market size and forecast, by Drug Origin
- 9.2.7.1.5. Market size and forecast, by Drug Type
- 9.2.7.2. Canada
- 9.2.7.2.1. Market size and forecast, by Class
- 9.2.7.2.2. Market size and forecast, by Spectrum of Activity
- 9.2.7.2.3. Market size and forecast, by Application
- 9.2.7.2.4. Market size and forecast, by Drug Origin
- 9.2.7.2.5. Market size and forecast, by Drug Type
- 9.2.7.3. Mexico
- 9.2.7.3.1. Market size and forecast, by Class
- 9.2.7.3.2. Market size and forecast, by Spectrum of Activity
- 9.2.7.3.3. Market size and forecast, by Application
- 9.2.7.3.4. Market size and forecast, by Drug Origin
- 9.2.7.3.5. Market size and forecast, by Drug Type
- 9.3. Europe
- 9.3.1. Key market trends, growth factors and opportunities
- 9.3.2. Market size and forecast, by Class
- 9.3.3. Market size and forecast, by Spectrum of Activity
- 9.3.4. Market size and forecast, by Application
- 9.3.5. Market size and forecast, by Drug Origin
- 9.3.6. Market size and forecast, by Drug Type
- 9.3.7. Market size and forecast, by country
- 9.3.7.1. Germany
- 9.3.7.1.1. Market size and forecast, by Class
- 9.3.7.1.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.1.3. Market size and forecast, by Application
- 9.3.7.1.4. Market size and forecast, by Drug Origin
- 9.3.7.1.5. Market size and forecast, by Drug Type
- 9.3.7.2. France
- 9.3.7.2.1. Market size and forecast, by Class
- 9.3.7.2.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.2.3. Market size and forecast, by Application
- 9.3.7.2.4. Market size and forecast, by Drug Origin
- 9.3.7.2.5. Market size and forecast, by Drug Type
- 9.3.7.3. UK
- 9.3.7.3.1. Market size and forecast, by Class
- 9.3.7.3.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.3.3. Market size and forecast, by Application
- 9.3.7.3.4. Market size and forecast, by Drug Origin
- 9.3.7.3.5. Market size and forecast, by Drug Type
- 9.3.7.4. Italy
- 9.3.7.4.1. Market size and forecast, by Class
- 9.3.7.4.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.4.3. Market size and forecast, by Application
- 9.3.7.4.4. Market size and forecast, by Drug Origin
- 9.3.7.4.5. Market size and forecast, by Drug Type
- 9.3.7.5. Spain
- 9.3.7.5.1. Market size and forecast, by Class
- 9.3.7.5.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.5.3. Market size and forecast, by Application
- 9.3.7.5.4. Market size and forecast, by Drug Origin
- 9.3.7.5.5. Market size and forecast, by Drug Type
- 9.3.7.6. Rest of Europe
- 9.3.7.6.1. Market size and forecast, by Class
- 9.3.7.6.2. Market size and forecast, by Spectrum of Activity
- 9.3.7.6.3. Market size and forecast, by Application
- 9.3.7.6.4. Market size and forecast, by Drug Origin
- 9.3.7.6.5. Market size and forecast, by Drug Type
- 9.4. Asia-Pacific
- 9.4.1. Key market trends, growth factors and opportunities
- 9.4.2. Market size and forecast, by Class
- 9.4.3. Market size and forecast, by Spectrum of Activity
- 9.4.4. Market size and forecast, by Application
- 9.4.5. Market size and forecast, by Drug Origin
- 9.4.6. Market size and forecast, by Drug Type
- 9.4.7. Market size and forecast, by country
- 9.4.7.1. Japan
- 9.4.7.1.1. Market size and forecast, by Class
- 9.4.7.1.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.1.3. Market size and forecast, by Application
- 9.4.7.1.4. Market size and forecast, by Drug Origin
- 9.4.7.1.5. Market size and forecast, by Drug Type
- 9.4.7.2. China
- 9.4.7.2.1. Market size and forecast, by Class
- 9.4.7.2.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.2.3. Market size and forecast, by Application
- 9.4.7.2.4. Market size and forecast, by Drug Origin
- 9.4.7.2.5. Market size and forecast, by Drug Type
- 9.4.7.3. India
- 9.4.7.3.1. Market size and forecast, by Class
- 9.4.7.3.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.3.3. Market size and forecast, by Application
- 9.4.7.3.4. Market size and forecast, by Drug Origin
- 9.4.7.3.5. Market size and forecast, by Drug Type
- 9.4.7.4. Australia
- 9.4.7.4.1. Market size and forecast, by Class
- 9.4.7.4.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.4.3. Market size and forecast, by Application
- 9.4.7.4.4. Market size and forecast, by Drug Origin
- 9.4.7.4.5. Market size and forecast, by Drug Type
- 9.4.7.5. South Korea
- 9.4.7.5.1. Market size and forecast, by Class
- 9.4.7.5.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.5.3. Market size and forecast, by Application
- 9.4.7.5.4. Market size and forecast, by Drug Origin
- 9.4.7.5.5. Market size and forecast, by Drug Type
- 9.4.7.6. Rest of Asia-Pacific
- 9.4.7.6.1. Market size and forecast, by Class
- 9.4.7.6.2. Market size and forecast, by Spectrum of Activity
- 9.4.7.6.3. Market size and forecast, by Application
- 9.4.7.6.4. Market size and forecast, by Drug Origin
- 9.4.7.6.5. Market size and forecast, by Drug Type
- 9.5. LAMEA
- 9.5.1. Key market trends, growth factors and opportunities
- 9.5.2. Market size and forecast, by Class
- 9.5.3. Market size and forecast, by Spectrum of Activity
- 9.5.4. Market size and forecast, by Application
- 9.5.5. Market size and forecast, by Drug Origin
- 9.5.6. Market size and forecast, by Drug Type
- 9.5.7. Market size and forecast, by country
- 9.5.7.1. Brazil
- 9.5.7.1.1. Market size and forecast, by Class
- 9.5.7.1.2. Market size and forecast, by Spectrum of Activity
- 9.5.7.1.3. Market size and forecast, by Application
- 9.5.7.1.4. Market size and forecast, by Drug Origin
- 9.5.7.1.5. Market size and forecast, by Drug Type
- 9.5.7.2. Saudi Arabia
- 9.5.7.2.1. Market size and forecast, by Class
- 9.5.7.2.2. Market size and forecast, by Spectrum of Activity
- 9.5.7.2.3. Market size and forecast, by Application
- 9.5.7.2.4. Market size and forecast, by Drug Origin
- 9.5.7.2.5. Market size and forecast, by Drug Type
- 9.5.7.3. South Africa
- 9.5.7.3.1. Market size and forecast, by Class
- 9.5.7.3.2. Market size and forecast, by Spectrum of Activity
- 9.5.7.3.3. Market size and forecast, by Application
- 9.5.7.3.4. Market size and forecast, by Drug Origin
- 9.5.7.3.5. Market size and forecast, by Drug Type
- 9.5.7.4. Rest of LAMEA
- 9.5.7.4.1. Market size and forecast, by Class
- 9.5.7.4.2. Market size and forecast, by Spectrum of Activity
- 9.5.7.4.3. Market size and forecast, by Application
- 9.5.7.4.4. Market size and forecast, by Drug Origin
- 9.5.7.4.5. Market size and forecast, by Drug Type
- CHAPTER 10: COMPETITIVE LANDSCAPE
- 10.1. Introduction
- 10.2. Top winning strategies
- 10.3. Product mapping of top 10 player
- 10.4. Competitive dashboard
- 10.5. Competitive heatmap
- 10.6. Top player positioning, 2022
- CHAPTER 11: COMPANY PROFILES
- 11.1. Abbott Laboratories
- 11.1.1. Company overview
- 11.1.2. Key executives
- 11.1.3. Company snapshot
- 11.1.4. Operating business segments
- 11.1.5. Product portfolio
- 11.1.6. Business performance
- 11.2. Alkem Laboratories Ltd.
- 11.2.1. Company overview
- 11.2.2. Key executives
- 11.2.3. Company snapshot
- 11.2.4. Operating business segments
- 11.2.5. Product portfolio
- 11.2.6. Business performance
- 11.3. Novartis AG
- 11.3.1. Company overview
- 11.3.2. Key executives
- 11.3.3. Company snapshot
- 11.3.4. Operating business segments
- 11.3.5. Product portfolio
- 11.3.6. Business performance
- 11.3.7. Key strategic moves and developments
- 11.4. Pfizer Inc.
- 11.4.1. Company overview
- 11.4.2. Key executives
- 11.4.3. Company snapshot
- 11.4.4. Operating business segments
- 11.4.5. Product portfolio
- 11.4.6. Business performance
- 11.5. Lupin
- 11.5.1. Company overview
- 11.5.2. Key executives
- 11.5.3. Company snapshot
- 11.5.4. Operating business segments
- 11.5.5. Product portfolio
- 11.5.6. Business performance
- 11.6. Teva Pharmaceutical Industries Limited
- 11.6.1. Company overview
- 11.6.2. Key executives
- 11.6.3. Company snapshot
- 11.6.4. Operating business segments
- 11.6.5. Product portfolio
- 11.6.6. Business performance
- 11.6.7. Key strategic moves and developments
- 11.7. Cipla Ltd
- 11.7.1. Company overview
- 11.7.2. Key executives
- 11.7.3. Company snapshot
- 11.7.4. Operating business segments
- 11.7.5. Product portfolio
- 11.7.6. Business performance
- 11.8. Bayer AG
- 11.8.1. Company overview
- 11.8.2. Key executives
- 11.8.3. Company snapshot
- 11.8.4. Operating business segments
- 11.8.5. Product portfolio
- 11.8.6. Business performance
- 11.9. F. Hoffmann-La Roche Ltd.
- 11.9.1. Company overview
- 11.9.2. Key executives
- 11.9.3. Company snapshot
- 11.9.4. Operating business segments
- 11.9.5. Product portfolio
- 11.9.6. Business performance
- 11.9.7. Key strategic moves and developments
- 11.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
- 11.10.1. Company overview
- 11.10.2. Key executives
- 11.10.3. Company snapshot
- 11.10.4. Operating business segments
- 11.10.5. Product portfolio
- 11.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 02. ORAL ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. GLOBAL BETA LACTAM AND BETA LACTAMASE INHIBITORS ORAL ANTIBIOTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. GLOBAL PENICILLIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 05. ORAL ANTIBIOTICS MARKET FOR QUINOLONE, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. ORAL ANTIBIOTICS MARKET FOR MACROLIDE, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 09. ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ANTIBIOTIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ANTIBIOTIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. GLOBAL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 12. ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS (CARTIS), BY REGION, 2022-2032 ($MILLION)
- TABLE 13. GLOBAL COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS (CARTIS) ORAL ANTIBIOTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 14. ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS (UTIS), BY REGION, 2022-2032 ($MILLION)
- TABLE 15. ORAL ANTIBIOTICS MARKET FOR DENTAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 16. ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 17. GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 18. ORAL ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 19. ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 20. ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 21. GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 22. ORAL ANTIBIOTICS MARKET FOR BRANDED, BY REGION, 2022-2032 ($MILLION)
- TABLE 23. ORAL ANTIBIOTICS MARKET FOR GENERIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 24. ORAL ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 25. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 26. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 27. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 28. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 29. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 30. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 31. U.S. ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 32. U.S. ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 33. U.S. ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 34. U.S. ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 35. U.S. ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 36. CANADA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 37. CANADA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 38. CANADA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 39. CANADA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 40. CANADA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 41. MEXICO ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 42. MEXICO ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 43. MEXICO ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 44. MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 45. MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 46. EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 47. EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 48. EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 49. EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 50. EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 51. EUROPE ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 52. GERMANY ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 53. GERMANY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 54. GERMANY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 55. GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 56. GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 57. FRANCE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 58. FRANCE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 59. FRANCE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 60. FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 61. FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 62. UK ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 63. UK ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 64. UK ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 65. UK ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 66. UK ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 67. ITALY ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 68. ITALY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 69. ITALY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 70. ITALY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 71. ITALY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 72. SPAIN ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 73. SPAIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 74. SPAIN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 75. SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 76. SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 77. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 78. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 79. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 80. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 81. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 82. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 83. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 84. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 85. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 86. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 87. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 88. JAPAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 89. JAPAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 90. JAPAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 91. JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 92. JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 93. CHINA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 94. CHINA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 95. CHINA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 96. CHINA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 97. CHINA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 98. INDIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 99. INDIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 100. INDIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 101. INDIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 102. INDIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 103. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 104. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 105. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 106. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 107. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 108. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 109. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 110. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 111. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 112. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 113. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 114. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 115. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 116. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 117. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 118. LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 119. LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 120. LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 121. LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 122. LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 123. LAMEA ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 124. BRAZIL ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 125. BRAZIL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 126. BRAZIL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 127. BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 128. BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 129. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 130. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 131. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 132. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 133. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 134. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 135. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 136. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 137. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 138. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 139. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
- TABLE 140. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
- TABLE 141. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 142. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
- TABLE 143. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
- TABLE 144. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 145. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 146. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 147. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 148. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
- TABLE 149. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 150. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
- TABLE 151. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 152. NOVARTIS AG: KEY EXECUTIVES
- TABLE 153. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 154. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 155. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 156. NOVARTIS AG: KEY STRATERGIES
- TABLE 157. PFIZER INC.: KEY EXECUTIVES
- TABLE 158. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 159. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 160. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 161. LUPIN: KEY EXECUTIVES
- TABLE 162. LUPIN: COMPANY SNAPSHOT
- TABLE 163. LUPIN: PRODUCT SEGMENTS
- TABLE 164. LUPIN: PRODUCT PORTFOLIO
- TABLE 165. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 166. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 167. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
- TABLE 168. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 169. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
- TABLE 170. CIPLA LTD: KEY EXECUTIVES
- TABLE 171. CIPLA LTD: COMPANY SNAPSHOT
- TABLE 172. CIPLA LTD: PRODUCT SEGMENTS
- TABLE 173. CIPLA LTD: PRODUCT PORTFOLIO
- TABLE 174. BAYER AG: KEY EXECUTIVES
- TABLE 175. BAYER AG: COMPANY SNAPSHOT
- TABLE 176. BAYER AG: PRODUCT SEGMENTS
- TABLE 177. BAYER AG: PRODUCT PORTFOLIO
- TABLE 178. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 179. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 180. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 181. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 182. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 183. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 184. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 185. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
- TABLE 186. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. ORAL ANTIBIOTICS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF ORAL ANTIBIOTICS MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN ORAL ANTIBIOTICS MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN ORAL ANTIBIOTICS MARKET (2023-2032)
- FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. MODERATE THREAT OF SUBSTITUTES
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL ORAL ANTIBIOTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. ORAL ANTIBIOTICS MARKET, BY CLASS, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR QUINOLONE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR MACROLIDE, BY COUNTRY 2022 AND 2032(%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook